Who We Are
At Acceleron, we are committed to patient health, safety and well-being. We value the patient voice in all of our decisions, and focus our research and development on disease where we can make a difference in the lives of patients with few or no effective therapeutic options.
We believe that timely disclosure of clinical study information is important to support medical research, educate physicians and participants, and generate confidence in the safety of investigational and newly approved medicines.
Acceleron is committed to publicly disclosing information about our clinical research trials.
Acceleron registers required clinical trial information for Acceleron-sponsored clinical studies on applicable registries, including Clinicaltrials.gov, the EU Clinical Trials Register, and other registry websites in compliance with applicable global, regional, and local regulations and industry association principles. Summary results of all Acceleron completed trials are also posted on the previously mentioned registries as a fundamental element of our policy.
Acceleron is committed to posting these results within 12 months of trial completion, regardless of the outcome of the trial, and providing summaries in a patient-friendly format that is easy to understand for our participants.
Acceleron is committed to complying with applicable national and international laws, regulations, and principles for clinical trial disclosure and transparency, including those put forth by industry associations and supported by independent research organizations and editors of leading peer-reviewed journals. Trust, honesty, and integrity are deeply important to how we operate.
Commitment to Diversity, Equity, and Inclusion
Diversity in Clinical Trials
Acceleron is an organization that values diversity, equity, and inclusion (DE&I). We strive to promote an inclusive culture in which our employees and the global population we serve feel welcome. We celebrate the contributions of each patient and their loved ones, clinicians, research scientists, and vendor partners. Your individuality is the key to innovative research, therapies, and cures.
To this end - Acceleron is committed to increasing enrollment of diverse populations within our clinical trials and product development efforts. We will champion this goal as we engage with external partners to address the needs of all patients, regardless of race, ethnicity, sex/gender, age, or any other characteristic that may serve as a barrier to clinical trial participation.
Together with MassBio, Acceleron has pledged to take meaningful action toward strengthening Diversity, Equity, and Inclusion.
More About Acceleron
Acceleron is dedicated to the discovery and development of innovative, life-changing medicines for patients with a wide range of serious and rare diseases. Our research focuses on harnessing the power of the TGF-beta protein superfamily, the target-rich area of biology behind the body’s remarkable capacity for cellular growth and repair.